Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy

Knapp, Maura; Tu, Xin; Wu, Ruiheng

doi:10.1038/s41401-018-0042-6

Cited by 213 publications

(179 citation statements)

References 107 publications

Supporting

Mentioning

157

Contrasting

Unclassified

Order By: Relevance

“…Hyperglycemia-induced microvascular changes are manifested as vascular endothelial defects and endothelial cell dysfunction, and they elicit a partial inflammatory response in the vascular endothelium [94]. These changes can affect glucose and insulin transport into cells, thereby inducing abnormal tissue function [18].…”

Section: Microvascular Function Of Cardiomyocytesmentioning

confidence: 99%

Exercise as A Potential Therapeutic Target for Diabetic Cardiomyopathy: Insight into the Underlying Mechanisms

Seo

Jang

et al. 2019

IJMS

View full text Add to dashboard Cite

Diabetes mellitus is associated with cardiovascular, ophthalmic, and renal comorbidities. Among these, diabetic cardiomyopathy (DCM) causes the most severe symptoms and is considered to be a major health problem worldwide. Exercise is widely known as an effective strategy for the prevention and treatment of many chronic diseases. Importantly, the onset of complications arising due to diabetes can be delayed or even prevented by exercise. Regular exercise is reported to have positive effects on diabetes mellitus and the development of DCM. The protective effects of exercise include prevention of cardiac apoptosis, fibrosis, oxidative stress, and microvascular diseases, as well as improvement in cardiac mitochondrial function and calcium regulation. This review summarizes the recent scientific findings to describe the potential mechanisms by which exercise may prevent DCM and heart failure.

show abstract

Section: Microvascular Function Of Cardiomyocytesmentioning

confidence: 99%

Exercise as A Potential Therapeutic Target for Diabetic Cardiomyopathy: Insight into the Underlying Mechanisms

Seo

Jang

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…Патологические процессы, возникающие вследствие гипергликемии, инсулинорезистентности и гиперинсули-немии, увеличивают риск развития диабетической КМП и СН при СД 2-го типа. Сложным остается определение индивидуального вклада каждого из этих факторов в развитие диабетической КМП [17,23,26,27].…”

Section: патофизиология сн при сд 2-го типаunclassified

Type 2 Diabetes Mellitus and Heart Failure: Innovative Possibilities for Management of Prognosis

et al. 2019

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM) has gone beyond the professional interests of one specialty. T2DM, cardiovascular (CV) diseases and chronic kidney disease, considered from the standpoint of a single cardio-reno-metabolic continuum, place a heavy economic burden on society. At the same time, the improvement of diagnostic methods and medical technologies led to distinct decrease in the frequency and mortality from a number of complications of T2DM, including myocardial infarction and stroke, but other states took their place. Thus, heart failure (HF) has taken the position of one of the most frequent complications with average prevalence of 24–40 % and significant predominance of HF with preserved ejection fraction (HFpEF). According to this paradigm, HFpEF is not a disease of diastolic dysfunction, but a systemic disease, the central element of which is impaired renal function. All this together has a potential value for choosing the optimal therapy. In recent years the results of specially designed studies assessing the CV-safety of antidiabetic drugs from the groups of dipeptidyl peptidase-4 (DPP4) inhibitors, glucagon-like preptide-1 (GLP-1) receptor agonists and sodium – glucose co-transporter-2 (SGLT2) inhibitors have become known. These drugs, except for SGLT2 inhibitors, by their mechanism of action affecting insulin resistance and hyperglycemia, demonstrated neutral or negative result on the frequency of hospitalizations due to HF. The EMPA-REG OUTCOME study with SGLT2, which has a special insulin-independent mechanism of action, demonstrated not only the efficacy and CV-safety of the drug in the form of a decrease in CV mortality by 38 %, but also a decrease in hospitalizations for HF by 35 %. Further studies with SGLT2 inhibitors confirmed positive effect on HF, indicating a class effect of the drugs. The recently completed study DECLARE-TIMI 58 proved the advantages of using dapagliflozin for the primary and secondary prevention of HF. This review highlights the prevalence of HF in diabetes mellitus, a new concept of the pathophysiology of HF, the main groups of sugar-lowering drugs and their effect on CV outcomes, in particular on HF.

show abstract

“…Hyperglycemia induced microvascular changes are manifested as vascular endothelial defects and endothelial cell dysfunction, and they elicit a partial inflammatory response in the vascular endothelium [86]. These changes can affect glucose and insulin transport into cells, thereby inducing abnormal tissue function [18].…”

Section: Microvascular Function Of Cardiomyocytesmentioning

confidence: 99%

Exercise as A Potential Therapeutic Target for Diabetic Cardiomyopathy: Insight into the Underlying Mechanisms

Seo

Jang

et al. 2019

Preprint

View full text Add to dashboard Cite

Diabetes mellitus is associated with cardiovascular, ophthalmic, and renal comorbidities. Among these, diabetic cardiomyopathy (DCM) causes the most severe symptoms and is considered to be a major health problem worldwide. Exercise is widely known as an effective strategy for the prevention and treatment of many chronic diseases. Importantly, the onset of complications arising from diabetes can be delayed or even prevented by exercise. Regular exercise is reported to have positive effects on diabetes mellitus and the development of DCM. The protective effects of exercise include the prevention of cardiac apoptosis, fibrosis, oxidative stress, and microvascular diseases, as well as improvement in cardiac mitochondrial function, and calcium regulation. The present review summarizes the recent findings to describe the potential mechanisms by which exercise may prevent DCM and heart failure.

show abstract

Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy

Cited by 213 publications

References 107 publications

Exercise as A Potential Therapeutic Target for Diabetic Cardiomyopathy: Insight into the Underlying Mechanisms

Exercise as A Potential Therapeutic Target for Diabetic Cardiomyopathy: Insight into the Underlying Mechanisms

Type 2 Diabetes Mellitus and Heart Failure: Innovative Possibilities for Management of Prognosis

Exercise as A Potential Therapeutic Target for Diabetic Cardiomyopathy: Insight into the Underlying Mechanisms

Contact Info

Product

Resources

About